Full Press Release Details
Kamada to Announce First Quarter Ended March
31, 2021 Financial Results and Host Conference Call on May 12, 2021
Rehovot, Israel, May 5, 2021 -- Kamada
Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for
the first quarter ended March 31, 2021, prior to the open of the U.S. financial markets on Wednesday, May 12, 2021.
Kamada management will host an investment community
conference call on Wednesday, May 12, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested
parties may participate in the conference call by dialing 877-407-0792 (from within the U.S.), or 201-689-8263 (International) and entering
the conference identification number: 13719388. The call will also be webcast live on the Internet on the Company's website at www.kamada.com.
will also be archived for 90 days on the Company's website at www.kamada.com.
Kamada Ltd. (the "Company") is a global
specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading
manufacturing capabilities. The Company's strategy is focused on driving profitable growth from its current commercial products,
its plasma-derived development pipeline and its manufacturing expertise, while evolving into a vertically integrated plasma-derived company.
The Company's two leading commercial products are GLASSIA and KEDRRAB . GLASSIA was the first liquid, ready-to-use, intravenous
plasma-derived AAT product approved by the FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals
Company Limited ("Takeda") and in other countries through local distributors. Pursuant to an agreement with Takeda, the Company
will continue to produce GLASSIA for Takeda through 2021 and Takeda will initiate its own production of GLASSIA for the U.S. market in
2021, at which point Takeda will commence payment of royalties to the Company until 2040. KEDRAB is an FDA approved anti-rabies immune
globulin (Human) for post-exposure prophylaxis treatment. KEDRAB is being marketed in the U.S. through a strategic partnership with Kedrion
S.p.A. The Company has additional four plasma-derived products administered by injection or infusion, that are marketed through distributors
in more than 15 countries, including Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company
has two leading development programs; a plasma-derived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus
disease (COVID-19) and an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe
clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence
in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently
added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected
to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the
Company's lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.
Chief Financial Officer
LifeSci Advisors, LLC